Erasca (ERAS)

Executive Summary

Erasca is a clinical-stage precision oncology company singularly focused on inhibiting the RAS/MAPK pathway, one of the most commonly mutated signaling cascades in cancer. The company's pipeline includes several novel agents, such as the SHP2 inhibitor ERAS-601, the ERK1/2 inhibitor ERAS-007, and the pan-RAF inhibitor naporafenib, which are being evaluated in multiple combination regimens across a range of solid tumors and hematologic malignancies. Erasca's most advanced program is the Phase 3 SEACRAFT trial of naporafenib in NRAS-mutant melanoma, with additional Phase 1/2 trials exploring synergistic combinations with targeted therapies and immunotherapies. Despite being early-stage, Erasca's deep focus on a validated but challenging pathway positions it to potentially address significant unmet needs, particularly in RAS-driven cancers that affect millions worldwide. However, the company faces typical clinical and regulatory risks, and no product has yet been approved. With a market capitalization around $4 billion, the stock reflects optimism about its novel pipeline but also carries high volatility given the binary nature of upcoming data readouts.

Upcoming Catalysts (preview)

• Q3 2026Interim data from Phase 1/2 trial of ERAS-007 + ERAS-601 in advanced solid tumors (NCT04866134)50% success
• Q3 2026Topline results from Phase 1b/2 trial of ERAS-601 + cetuximab + pembrolizumab in advanced solid tumors (NCT04670679)45% success
• H2 2026Regulatory update or interim analysis from Phase 3 SEACRAFT trial of naporafenib in NRAS-mutant melanoma55% success